Pfizer gets full US FDA nod for LORBRENA as first-line treatment for ALK-Positive metastatic NSCLC EP News Bureau Mar 4, 2021 Approval is based on CROWN trial, which showed a 72 per cent reduction in risk of progression or death for treatment with LORBRENA…
